Regeneron’s current growth contributors treat inflammatory conditions from eczema to asthma, retinal disease, and cancer immunotherapy.

“Regeneron has a rich pipeline, including many late-stage programs in areas spanning hematology, immunology, and rare disease. This should fuel new stages of growth down the road — even if only a handful make it to commercialization.”

“Today, Vertex’s drugs may treat 90% of the cystic fibrosis patient population, and the company is working on a candidate to address those who can’t benefit from its current products.Vertex has strong intellectual property that should protect its cystic fibrosis leadership into the later part of the next decade.”